Hartford Business Journal

HARTFORDBUSINESS.COM | FEBRUARY 9, 2026 15 COMPLETE CATALOG 1-800-295-5510 uline.com π OUR MATS ARE MAN'S (SECOND) BEST FRIEND ORDER BY 6 PM FOR SAME DAY SHIPPING 25_014892_Hartford_Business_Journal_FEB Mod: December 16, 2025 2:58 PM Print: 12/18/25 page 1 v2.5 Good said Endo didn't plan to pursue the drug's development. "So (Sciascia) and I bought it out with personal money and started it literally at our kitchen tables," she said, adding that Endo's board also provided some angel investment funding. Good emphasized that while Haduvio falls within the opioid cate- gory, it's a "mixed agonist" — a type of opioid drug that is not addictive in the way oxycodone is. "This drug we have was designed to basically get away from addiction," she said. Good said she and Sciascia were drawn to the compound because it offered the possibility of opioid-like efficacy without the downside. "Tom and I were interested in this compound because we were hoping you'd get the efficacy of opioids without the baggage of addiction," she said. Phase 3 So far, Trevi's clinical results have supported that early optimism. Just as importantly, Haduvio has been developed as a twice-daily oral drug, making it easier for patients to take than more complex therapies. Physicians who treat IPF patients say chronic cough remains one of the most difficult symptoms to manage. Philip Molyneaux, a professor of pulmonary medicine at Royal Brompton Hospital in London and an investigator in the Haduvio trials, said the condition is a persistent chal- lenge in clinical care. "Chronic cough continues to repre- sent a major unmet need in the care of my patients with IPF and imposes a significant burden on their day-to-day lives," Molyneaux said. He said Haduvio's trial results are encouraging because they show patients are coughing less and also feel better, supporting continued study of the drug. Trevi is preparing to launch a pivotal Phase 3 trial focused on IPF patients, which the company expects to begin in the first half of this year. As of the end of the third quarter, Trevi reported $194.9 million in cash, cash equivalents and marketable securities. Good said that gives the company ample resources to fund the Phase 3 program, though she expects Trevi will eventually need to raise additional capital and expand its workforce as it moves closer to commercialization. If the Phase 3 trials are successful, the next step would be seeking approval from federal regu- lators — a process that concerns Good amid ongoing leadership turnover at the U.S. Food and Drug Administration. She said the FDA has changed directors of its Center for Drug Evaluation and Research six times over the past year. "When you're in a five- to 10-year (drug) development program, you can't have six different leaders because they all have different views," she said. "For companies like us, it's really frustrating, because it's really difficult to get solid advice that you're confident is going to stick." Good said she also worries about politics influencing regulatory decision-making. "I do have a lot of worries about it," she said. "I think anytime politics creeps into scientific discussions, that's probably not a good thing." Ultimately, Good said her confi- dence rests with the drug itself and the relief it could bring to patients who currently have no effective treatment options. Helping people whose constant coughing is "ruining their day-to-day lives," she said, "is really motivating." Trevi occupies the 16th floor of 195 Church St. in New Haven, overlooking the New Haven Green. Photo | CoStar

• Cover